This clinical trial is focused on treating patients with a severe brain injury, specifically those experiencing a disorder of consciousness. The study will use a medication called apomorphine hydrochloride, which is administered as a solution for infusion through a subcutaneous injection. This means the medication is given under the skin. The purpose of the study is to understand how effective this treatment is for patients who have difficulty being aware of themselves or their surroundings due to their brain injury.

Participants in the study will receive either the apomorphine hydrochloride treatment or a placebo, which is a substance with no active medication. The study will last for a period of up to 30 days. During this time, researchers will monitor changes in the patients’ conditions using various methods, including the Coma Recovery Scale, which helps assess the level of consciousness. Other assessments may include changes in brain activity measured by EEG (a test that detects electrical activity in the brain), and imaging techniques like MRI and PET scans, which provide detailed pictures of the brain.

The study aims to determine if apomorphine hydrochloride can improve the condition of patients with severe brain injuries by enhancing their level of consciousness. Researchers will also look at other factors such as sleep patterns and body temperature changes to gain a comprehensive understanding of the treatment’s effects. The trial is expected to continue until 2028, providing valuable insights into the potential benefits of this treatment for individuals with severe brain injuries.